Every year, 2.3 million newborns die from causes we already know how to treat. It's not clinical failure. It's infrastructure failure.

Neopenda is a commercial medical device company at the turning point between early traction and scale.

We build vital signs monitoring technology for hospitals that operate with too few nurses, too many patients, and too little margin for error, starting with newborns in Africa.

The hardest risks are behind us. The biggest value creation is ahead.

Every day, patients die from causes that are preventable and treatable, not because clinicians don't know what to do, but because deterioration happens silently between checks.

In top U.S. hospitals, a nurse cares for 2 patients at a time. In many emerging markets, that ratio is 20-to-1 or worse. Clinical research shows that adding just one extra patient per nurse increases mortality by 16%.

When you're the only nurse in a crowded ward surrounded by fragile lives, you can't catch what you can't see. Patients deteriorate silently, care becomes reactive, and lives are lost, not because treatment doesn't exist, but because visibility does.

Now imagine you are that nurse. It's the middle of the night, the ward is full, and you have no equipment to tell you who needs you most. Somewhere in that room, a baby's oxygen is dropping. By the time you notice, the window for intervention may have passed.

This is the reality for millions of hospitalized newborns. Not a failure of medicine, a failure of infrastructure.

neoGuard is a vital signs monitoring system purpose-built for real-world hospitals, giving clinicians the three scarcest resources in healthcare: visibility, prioritization, and time.

1. Medical-grade wearable monitors track pulse rate, oxygen saturation, respiratory rate, and temperature.
2. Data streams wirelessly to a centralized dashboard, giving one nurse visibility across an entire ward.
3. Built-in localization helps staff find the right patient instantly.

In healthcare, minutes matter. neoGuard turns blind spots into action, and reactive care into proactive intervention.

Most patient monitors weren't built for real-world hospitals. They assume stable power, low patient density, and constant maintenance, and in many emerging markets, that's exactly why they end up abandoned, broken, or locked away in equipment graveyards.

We didn't retrofit Western hospital equipment. We started from scratch, spending years on the ground across dozens of hospitals, working alongside 1,000+ clinicians to design for the environments that need it most:

1. Built-in battery life to withstand frequent power outages
2. Durable and cleanable for overcrowded, high-turnover wards
3. Affordable and scalable for facilities with limited budgets

The result is a system that is durable, intuitive, and affordable, and actually gets used.

neoGuard is no longer an experiment or a pilot, it's a commercially deployed, regulated medical device trusted in clinical settings across multiple countries.

1. CE Mark (Class IIb, EU), PPB clearance (Kenya), and TMDA clearance (Tanzania)
2. ISO 13485 certified quality management system
3. Patented in the U.S., Japan, and Kenya
4. Qualified by the WHO and UNITAID as an innovative technology for low-resource settings

The regulatory heavy lifting is done. What remains is scale.

e've moved decisively beyond early experimentation. neoGuard is now embedded in routine hospital care, delivering continuous monitoring at scale:

1. 5,000+ patients monitored
2. 500+ devices sold across 40+ customer facilities
3. 150,000+ hours of monitoring logged
4. 53% year-over-year revenue growth in Kenya
5. 433% YoY growth in monitoring hours

Hospitals aren't evaluating neoGuard, they're using it.

Neopenda's growth strategy is built on a simple truth: in healthcare, trust travels. We enter hospitals through neonatal wards, the highest acuity, highest scrutiny environment, and let clinical outcomes do the selling.

From there, adoption expands ward by ward within facilities, spreads organically through peer referrals between hospitals, and ultimately converts into institutional procurement at the government and NGO level.

This model converts clinical trust into repeatable revenue, creating a durable growth engine built to scale across health systems, not just single facilities. This isn't theory, here's what embedded adoption looks like in practice:

1. 558 clinicians trained across multi-country operations, and counting.
2. 94% of users report neoGuard as their primary tool for reducing manual monitoring.
3. 81% of clinicians demand permanent integration into hospital processes.
4. 100% real-time clinical data captured across every deployment.

Hospital administrators aren't moved by mission statements, they're accountable to budgets, staff capacity, and patient outcomes. neoGuard earns its place because it solves real operational problems:

1. Clinicians can prioritize the sickest patients without relying on instinct alone
2. Missed deterioration events are reduced before they become emergencies
3. Staff workload decreases without adding new burden or training overhead

The result is a device that doesn't just get purchased, it gets used, trusted, and eventually demanded. Once installed, neoGuard becomes essential infrastructure.

Starting with newborns was a deliberate strategic choice. Neonatal care carries the highest clinical risk, the strictest regulatory requirements, and the lowest tolerance for failure. By succeeding here first, we cleared the hardest hurdles upfront, and proved that we can execute in the most demanding clinical environments on earth.

That foundation now unlocks something much larger. We are defining a new category of continuous patient monitoring built for environments where reliability, simplicity, and uptime matter more than feature density, and the same infrastructure that monitors newborns today is the platform that scales across pediatrics, maternity, and general wards tomorrow.

Monitoring is the entry point. Stronger systems are the outcome.

We start with the hardest problem, and expand outward into a global platform.

Today we are selling into a $188M market for in-patient neonatal monitoring in Sub-Saharan Africa, where 70% of hospitals still have no continuous monitoring solution.

From there, our expansion path is clear: a $5.7B near-term market for neonatal and pediatric monitoring across global emerging markets, and a $35.8B long-term platform opportunity in patient monitoring across all ages and care settings worldwide.

We entered through the hardest door. The rest opens from here.

neoGuard doesn't just monitor patients, it captures continuous, high-fidelity clinical data that no one in these settings has ever had access to before. Over time, that data layer becomes something far more powerful than a monitoring device:

1. Earlier detection of deterioration before it becomes a crisis
2. Smarter prioritization of clinical resources across entire wards
3. System-level visibility that helps health systems anticipate risk and intervene sooner

This is the platform opportunity. From a single device at the bedside to an intelligence layer across entire health systems, from saving individual lives to strengthening the infrastructure that protects all of them.

Neopenda's team spans Kenya, Nigeria, the United States, and Argentina, because building technology that works in the real world requires people who understand it firsthand.

Our biomedical engineers, pharma executives, and market builders bring careers shaped by Medtronic, GlaxoSmithKline, Eli Lilly, and Columbia University, combined with thousands of hours on the ground in the hospitals we serve.

We don't just understand the problem from the outside. We live and work in the communities where neoGuard is deployed.

The medtech market is demonstrating strong appetite for validated clinical technology at scale. Recent IPOs including Ceribell (CBLL) and Kestra (KMTS) illustrate viable public market pathways for companies in our space, while investors in pediatric and wearable health technology, such as those backing Kiddo Health, are transacting at high multiples.

Strategic acquirers including large medtech players and global health-focused funds have a consistent track record of acquiring proven emerging market health infrastructure. Neopenda is committed to delivering returns for its investors and is building toward multiple viable exit pathways.

Most startups ask you to invest in possibility. Neopenda offers momentum.

The technical risk is gone, neoGuard is patented, regulated, and deployed in real hospitals. The market risk is shrinking fast, sales are growing, adoption is repeatable, and expansion is underway. Capital now accelerates revenue, not R&D.

And the platform upside is just beginning. Early investors participate before recurring revenue and data economics are fully priced in.

But this round is about more than returns. Where you live shouldn't determine whether you live, and we're inviting our community of clinicians, parents, supporters, and everyday investors to be part of changing that. By investing in Neopenda, you're backing a proven product, a growing business, a massive underserved market, and a team already executing on the ground.

We're entering the phase where every dollar works harder. We'd love for you to be part of what comes next.

This community round is a strategic component of our broader raise.

Its role is to pull forward the commercial milestones that convert demand into repeatable revenue, laying the foundation for company-level profitability.

The medtech market is demonstrating strong appetite for validated clinical technology at scale. Recent IPOs including Ceribell (CBLL) and Kestra (KMTS) illustrate viable public market pathways for companies in our space, while investors in pediatric and wearable health technology, such as those backing Kiddo Health, are transacting at high multiples.

Strategic acquirers including large medtech players and global health-focused funds have a consistent track record of acquiring proven emerging market health infrastructure. Neopenda is committed to delivering returns for its investors and is building toward multiple viable exit pathways.